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Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA,
and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese
Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK
for the following reasons. First, although the daily dose of 150e200 mg was approved in Japan, recent PK-
PD studies revealed that higher serum concentration is required to achieve better clinical efﬁcacy and
several ﬁndings concerning the usefulness of higher dosage regimen have obtained recently. Second,
although maximal concentrations that obtained immediately after the end of administration (Cmax) was
generally adopted, the serum concentration at 1 h after initiation of administration [peak serum con-
centration (Cpeak)] proved to be more suitable as an efﬁcacy indicator of aminoglycosides. Lastly, as ABK is
approved only in Japan, no international practice guideline for TDM has not been available in ABK to date.
This guideline evaluated the scientiﬁc data associated with serum ABK monitoring and provided rec-
ommendations based on the available evidence. Potential limitations of this guideline, however, include
the ﬁndings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSA
infections and that most of the published literature describes observational studies.
 2013, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
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Grading system for ranking recommendations and evidence level adopted in the
guideline.
Category, grade Deﬁnition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C1 Recommendation for use regardless of poor evidence
C2 Poor evidence to support a recommendation for use
D Good-to-moderate evidence to support a recommendation
against use
Quality of evidence
I Evidence from 1 properly randomized, controlled trial
II Evidence from 1 well-designed clinical trial, without
randomization from cohort or case-controlled analytical
studies, multiple time-series, or dramatic results from
uncontrolled experiments.
III Evidence from opinions of respected authorities, based on
clinical experience, descriptive studies, or reports of expert
committeesArbekacin (ABK) is a derivative of dibekacin, developed in Japan,
with speciﬁc activities against bothgram-positive andgram-negative
bacteria [1]. ABK is an effective aminoglycoside antibiotic against
methicillin-resistant Staphylococcus aureus (MRSA) [2,3]. MIC80 of
ABK against the MRSA isolates was 1 mg/mL. Nephrotoxicity is one of
themain adverse events associatedwith ABKuse [4]. Comparedwith
other antimicrobial agents, the therapeutic range is relatively narrow
in ABK, and therapeutic drug monitoring (TDM) is required for
maximizing efﬁcacy while minimizing the onset of toxicities.
ABK was approved and widely used in Japan for treatment of
patients infected with MRSA, and TDM was introduced in clinical
practice. The Japanese Society of Chemotherapy (JSC) and the Jap-
anese Society of Therapeutic Drug Monitoring (JSTDM) decided to
develop clinical practice guidelines for TDM of ABK for the
following reasons. First, although the daily dose of 150e200 mg
was approved in Japan, recent PK-PD studies revealed that higher
serum concentration is required to achieve better clinical efﬁcacy
and several ﬁndings concerning the usefulness of higher dosage
regimen have obtained recently.
Second, although maximal concentrations that obtained
immediately after the end of administration (Cmax) was generally
adopted, the serum concentration at 1 h after initiation of admin-
istration [peak serum concentration (Cpeak)] proved to be more
suitable as an efﬁcacy indicator of aminoglycosides [5e7]. Lastly, as
ABK is approved only in Japan, no international practice guideline
for TDM has not been available in ABK to date.
This guideline evaluated the scientiﬁc data associated with
serum ABK monitoring and provided recommendations based on
the available evidence. Potential limitations of this guideline, how-
ever, include the ﬁndings that few prospective clinical trials of TDM
of ABK are available in the treatment of MRSA infections and that
most of the published literature describes observational studies.2. Methods
Clinical practice guidelines for TDM of ABK were reviewed by
a practice guideline committee which consisted of 18 experts in
TDM convened from the JSC and JSTDM. The committee
completed a review of papers published since 2000 and analyzed
the data prior to 1999 additionally if necessary. In evaluating the
evidence regarding TDM, the committee followed the Canadian
Task Force [8], including a systematic weighting of the quality of
the evidence and recommended grade of recommendation by the
classiﬁcation of Minds which is abbreviation of Medical Infor-
mation Network Distribution Service, ﬁnancially supported by
Ministry of Health, Labor and Welfare of Japan as a consignment
project (Table 1).
Computerized literature searches of PUBMED of the English-
language literature and of Igaku Chuo Zasshi of the Japanese-
language literature were performed using the terms “arbekacin”,
“therapeutic drug monitoring” and focused mainly on human
studies. However, animal studies and in vitro data were included if
necessary. The committee speciﬁcally looked for existing random-
ized clinical trial and existing meta-analysis using general database
(i.e., MEDLINE, EMBASE), and the Cochrane Library (both The
CochraneDatabase of Systematic Reviews andDatabase of Abstracts
of Reviews of Effectiveness). However no randomized clinical trials
andmeta-analysiswere available andmany recommendationswere
developed from observational studies or small case studies.
The committee discussed in person on 7 occasions and by e-mail
via mailing lists. Draft guidelines of the executive summary were
uploaded to the home page of JSC and JSTDM. Feedback fromexternal public comments was obtained between April 9th 2012
and May 8th 2012. The guideline in the Japanese version was
approved by the JSC and JSTDM Board of Directors and was pub-
lished in the Japanese Journal of Chemotherapy in June 2012.
Allmembers of the clinical practice guideline committee complied
with the JSCpolicyonconﬂicts of interest,whichrequiresdisclosureof
any ﬁnancial or other interest thatmight be construed as constituting
an actual, potential, or apparent conﬂict. Potential conﬂicts of interest
are listed in theAcknowledgments section.At three-year intervals, the
committee will determine the need for revisions to the guidelines.
2.1. Indication of TDM
2.1.1. Executive summary
a. TDM is performed in patients who are likely to receive courses
of ABK therapy of more than 4 days in patients in whom ABK is
administered at a dosing frequency of once daily (C1-III).
b. TDM should be planned from the start of ABK therapy in pa-
tients with serious infections, intensive dosing of ABK,
impaired renal function/hemodialysis, and unstable (deterio-
rating or improving) renal function. TDM is also performed
when adverse events occur or no favorable clinical response
obtains. (B-II)2.1.2. Literature review
In a retrospective study that analyzed PK-PD of once a daily
administration of ABK in patients with pneumonia caused by MRSA,
high Cpeak was revealed to be a signiﬁcant indicator of the clinical
efﬁcacy [odds ratio (OR) ¼ 1.27], and high trough value was an in-
dependent risk factor for the development of renal dysfunction
(OR ¼ 2.00) [9]. Kawano and Tanigawara reported that Cmax values
were 14.7 mg/mL and 8.4 mg/mL in patients who received ABK at the
dose of 150e200 mg once daily and those who received the same
dose twice daily, respectively. The proportion of responders was
higher in patients with once daily administration than that of twice
daily group [10]. As no apparent TDM target representing the efﬁcacy
is available, and recommendation of its use was discourage based on
the PK-PD characteristics, description of divided daily administration
such as 100 mg twice daily were not included in this guidelines.
In a post market survey of patients in whom the blood ABK
concentration was monitored, almost all adverse effects developed
within 7 days after administration (adults: 45/64, children: 2/2)
[10]. Mainly from the aspect of adverse events, the committee
recommended performance of TDM in patients in patients who are
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TDM, however, should be considered in patients at a high risk of
nephrotoxicity regardless of possible duration of therapy. As earlier
amendments are required to facilitate rapid attainment of the
target trough concentration in patients with serious or complicated
infections, TDM should be planned from the start of ABK therapy.
2.2. Pharmacokinetics-pharmacodynamics (PK-PD)
2.2.1. Executive summary
It is desirable to evaluate the clinical and bacteriological effects
based on Cpeak/minimum inhibitory concentration (MIC) (C1-III).
Most of previous studies, however, evaluated clinical outcomes
using the maximum blood concentration (Cmax), and available data
from Cpeak are limited.
2.2.2. Literature review
Cmax which is a term used in pharmacokinetics, refers to the
maximal concentration that a drug achieves immediately after the
completion of drug administration. Different from Cmax, Cpeak is
assessed after completion of distribution equilibrium between the
drug in tissues and in plasma. It is desirable to evaluate the clinical
and bacteriological effects based on Cpeak/MIC [9e12].
Most previous studies were evaluated Cmax as an indicator of
clinical efﬁcacy. On classiﬁcation and regression tree (CART) anal-
ysis, the Cmax/MIC cut-off value for the clinical effect was identiﬁed
as 7.4. Although no signiﬁcant difference was noted, the response
ratewas 88.9% in the groupwith avalue higher than 7.4, and 71.4% in
the group with a value of 7.4 or lower [10]. In a survey of the rela-
tionship between the PK-PD parameters and clinical efﬁcacy in pa-
tients with MRSA pneumonia treated by ABK, Cmax/MIC 8 was a
crucial factor of clinical efﬁcacy (OR ¼ 27.2), and Cmax/MIC was an
independent factor correlated with the bacteriological effect
(OR ¼ 1.68) [11]. In a multicenter open clinical study of once-a-day
administration of 200 mg of ABK for the treatment MRSA infec-
tion, a high clinical effect was demonstrated in patients with Cmax/
MIC > 7e8. (response rate: Cmax/MIC 7, 75.0%; 8, 80.0%) [12].
Recent clinical studies evaluated mainly Cpeak as referred to here-
inafter. Kobayashi et al. reported that the median Cpeak/MIC in the
bacteriological responder groupwas8.6 (range: 3.1e18.5) inABK [9].
2.3. Methods of TDM
2.3.1. Executive summary
a. Since steady state of ABK is achieved earlier than those of van-
comycin and teicoplanin, it is possible to draw TDM samples
prior to the second dose (on day 2) in patients with a normal
renal function who are administered once daily. However, it is
practical to obtain samples on day 3 in consideration of patients
with impaired renal function or in whom ABK is started in the
afternoon (C1-III).
b. Weekly monitoring is recommended after initial TDM. More
frequent follow-up trough monitoring is required in patients
with amendment of dosing regimen, hemodynamic instability,
unstable renal function (i.e. deteriorating or improving), and at
high risk for nephrotoxicity. (C1-III)
c. To determine the trough concentration, blood sample is
collected within 30 min before administration. To measure
Cpeak, it is recommended to draw blood samples one hour after
the initiation of infusion (30 min after completion when ABK is
administered for 30 min). (C1-III)
d. Troughconcentrationsareused tomonitor fornephrotoxicity (B-II).
e. The association of ototoxicity with the concentration of ABK or
total dose administered is not determined (unresolved issue).2.3.2. Literature review
Trough concentrations should be assessed at steady state. The
mean half-life of ABK has been reported to be 3.5 h in subjects with
a normal renal function [creatinine clearance (Ccr) 80 mL/min],
4.0 h in patients with mild renal dysfunction (Ccr: 50e80 mL/min),
and 16.8 h in patients with moderate/severe renal dysfunction
(Ccr < 50 mL/min) [12]. The time to reach a steady state calculated
from these half-lives was approximately 18 h, 20 h, and 84 h,
respectively. According to these PK analysis, TDM results on day 2
can be evaluable as a steady state in patients with a normal renal
function and mild renal dysfunction.
Tanigawara et al. reported that ABK clearance was related to Ccr,
age, and body weight. The volume of distribution was different in
healthy subjects and infected patients, and this difference was
more pronounced among disease types [13]. Ikeda et al. [14] re-
ported that duration time of infusion, Ccr, body mass index (BMI),
serum albumin level, and presence of chronic heart failure were
signiﬁcant factors inﬂuencing Cpeak. Based on these ﬁndings,
frequent follow-up TDM is recommended for patients with severe
infection, impaired renal function, obesity or underweight,
concomitant use of nephrotoxic agents (aminoglycosides, ampho-
tericin B, cyclosporine, contrast media, etc.), and particular clinical
conditions which cause ﬂuctuating volumes of distribution.
In a nationwide questionnaire survey (203 institutions) con-
cerning TDM of ABK, Cmax was used in 88 institutions, and Cmin was
used in 79 institutions as the target serum concentrations that
indicate clinical efﬁcacy [15]. Although previous reports mainly
analyzed based on Cmax, recent studies used Cpeak as an indicator of
clinical efﬁcacy [4,9e12,16,17]. Regarding the optimum adminis-
tration method of ABK based on the PK-PD theory, it has been re-
ported that the trough concentration (OR ¼ 2.00) and patient’s age
(OR¼ 1.06)were indices of the development of renal dysfunction on
multiple logistic regression analysis. The mean trough concentra-
tionswere2.6mg/mL inpatientswithdevelopingnephrotoxicity and
0.5 mg/mL in patients without nephropathy [9]. Sato et al. described
that incidences of nephrotoxicity were 2.5%, 5.2%, and 13.1% in pa-
tients with a trough value of 1 mg/mL, 2 mg/mL, and 5 mg/mL,
respectively [4]. As for ototoxicity, Suzuki et al. demonstrated that
there was no signiﬁcant correlation between auditory brainstem
response abnormalitywith eitherpeakABKconcentration20mg/mL,
trough concentration 4 mg/mL, or total dose100 mg/kg [18].2.4. Target of serum concentrations in TDM
2.4.1. Executive summary
a. Clinical effect can be expected when the Cmax/MIC ratio was 8 or
higher, and target Cpeak of 15e20 mg/mL is recommend (C1-III).
b. Trough concentrations of >2 mg/mL are not recommended
because of the risk of nephrotoxicity. (B-II)2.4.2. Literature review
In studies using Cmax as an indicator of clinical efﬁcacy in pa-
tients with once daily administration at the approved dose of 150e
200 mg, Kawano et al. [10] reported that the mean Cmax was
14.7 mg/mL, and the mean trough concentration was 0.74 mg/mL.
Aikawa et al. [12] described that the mean Cmax and trough con-
centration were 16.2 and 1.1 mg/mL, respectively. Sato et al. [4]
performed PK-PD analysis involving 174 patients with MRSA
infection. On logistic regression analysis, the efﬁcacy was high
when Cmax was 7.9e12.5 mg/mL (OR ¼ 6.7), and the incidences of
nephrotoxicity were 2.5, 5.2, and 13.1% in patients with a trough
value of 1, 2, and 5 mg/mL, respectively.
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strains with an MIC of 2 mg/mL. Considering maximal concentra-
tions that a drug achieves immediately after the completion of
drug administration (Cmax) are higher than concentrations after
completion of distribution (Cpeak), Cpeak must be lower than 15 mg/
mL in aforementioned studies using Cmax. Three clinical studies
targeting a higher Cpeak have recently been reported. Firstly,
Kimura et al. [16] performed a clinical study setting the target
Cpeak of ABK at 15e20 mg/mL in patients with pneumonia and
sepsis caused by MRSA. The mean Cpeak was 17.2 mg/mL, and the
rate of patients with a trough value of <2 mg/mL was 87.2% (34/
39). A favorable response was achieved in 35 of 43 patients
(81.4%). Secondly, Yamamoto et al. [17] performed a prospective
clinical study, setting the target Cpeak and trough value at 20 and
<2 mg/mL, in patients with pneumonia and bacteremia caused by
MRSA. The mean Cpeak was 22.7  5.5 mg/mL, a clinical and
bacteriological effect was obtained in 66.7% (6/9), and 62.5% (5/8),
respectively. Lastly, Matsumoto et al. set initial target Cpeak at 15e
20 mg/mL and evaluated clinical efﬁcacy and safety of ABK in pa-
tients with MRSA sepsis and pneumonia. The mean Cpeak was
16.2 mg/mL, and the efﬁcacy rate was 89.7% [19].
2.5. Initial administration plan
2.5.1. Executive summary
a. Once daily administration is recommended from efﬁcacy and
safety viewpoints (B-II).
b. A single dose of 200 mg/day has been approved. Experts recom-
mend 300 mg/day (5.5e6.0 mg/kg) to reach the target concen-
tration. (C1-III) However evidence concerning its safety is limited.
c. Dose is determined based on the ideal body weight. For patients
with morbid obesity, the corrected body weight should be
adopted (C1-III).2.5.2. Literature review
The ideal and corrected body weights are calculated using the
equations below:
Ideal body weight : Ideal body weightðkgÞ
¼ HeightðmÞ  heightðmÞ  22
Corrected body weight [20]:
Underweightðactual body weight=ideal body weight < 1Þ
: Actual body weight 1:13
Overweightðmorbid obesityÞðactual body weight=
ideal body weight > 2Þ : 0:43ðactual body weight
 ideal body weightÞ þ ideal body weight
The clinical response rates in patients who were administered
150e200 mg once daily were 89.5% in bacteremia and 80.8% in
pneumonia, and these tended to be higher than those in patients
with twice daily administration of same total daily dose of ABK
(66.7% in bacteremia and 66.7%, in pneumonia) [10,21]. In an efﬁ-
cacy evaluation of 200 mg once daily administration of ABK in
patients with MRSA pneumonia, clinical and bacteriological effects
were obtained in 74.4% and 46.2%, respectively [12]. In another
study in 111 patients with pneumonia caused byMRSA treated with
200 mg/day of ABK, the clinical response rate was signiﬁcantly
higher in once daily administration group compared with twice
daily group (69.6% vs. 50.8%) [9].Asmentioned above, target Cpeak 15e20 mg/mLwas not achieved
withoncedailyadministrationof the approveddoseof 150e200mg,
andhigher dosing regimen is required to improve clinical efﬁcacy. In
three clinical studies targeting a higher Cpeak, Kimura et al. [16]
prepared nomogram based on parameters of population pharma-
cokinetics in consideration of the body weight, renal function, and
age. With 5.8 mg/kg administration, the mean Cpeak was achieved
17.2 mg/mL. Yamamoto et al. [17] set initial dose at a level expected to
yield the goal peak of 20 mg/mL and a trough level of less than 2 mg/
mL, using software. Mean initial dosewas calculated to be 269.2 mg
(5.9mg/kg) inpatientswhosemean bodyweightwas 45.8 11.2 kg,
andCpeakwas22.75.5mg/mL in the6 responders and20.96.0mg/
mL in the 3 non-responders. Incidence of adverse effects was 38.5%,
and 3 of 13 patients experienced renal dysfunction.
Matsumoto et al. showed sufﬁcient clinical efﬁcacy is obtained
by setting Cpeak at 15e20 mg/mL. Mean initial dose per actual
body weight was 5.6 mg/kg, and mean initial Cpeak was 16.2 mg/
mL (44% of patients achieved 15e20 mg/mL or higher). The trough
concentration was 1.1  1.5 mg/mL in all patients subjected to
efﬁcacy analysis, and 2.3  2.9 mg/mL in patients with adverse
reaction. Recommendation of initial dose per actual body weight
to achieve target Cpeak is considered to be inevitable issue in this
guidelines. Although sufﬁcient number of patients was not
assessed regarding dosing regimen targeting a higher Cpeak,
committee recommended 5.5e6.0 mg/kg from these 3 clinical
studies targeting a higher Cpeak.
As for safety stand point in targeting a higher Cpeak, Yamamoto
et al. reported that adverse effects occurred in38.5%of patients, and3
of 13 patients experienced renal dysfunction [17]. In the study by
Matsumot et al., adverse events occurred in 6 (20.7%) of 24 patients
subjected to analysis until the end of administration. Renal disorder
was observed in only 2 patients. The deﬁnition of renal toxicity,
however, was not mentioned clearly in these reports. A reasonable
composite from the literature deﬁnes this adverse effect as an in-
crease of >0.5 mg/dL or a 50% increase in serum creatinine over the
baseline in consecutivelyobtaineddaily serumcreatinine values [22].
To provide enough evidence of safety conﬁrm the safety in the
treatment with high dose of ABK, additional studies are required.
2.6. TDM in patients under particular clinical conditions and
pediatric considerations
2.6.1. Executive summary
a. Patients with impaired renal function: No particular recom-
mendation has been obtained regarding the dosing regimen of
ABK in patients with impaired renal function (unresolved issue).
b. Hemodialysis (HD): No consensus is obtained regarding the
dosing regimen of ABK in patients with HD (unresolved issue).
c. Pediatric considerations:
1) Clinicians should consider postconceptual age (PCA), serum
creatinine level, body weight when determining the initial
antibiotic dosing regimen for neonates. (C1-III).
2) Initially ABK is administered at 4e6 mg/kg/day (dosing in-
terval: 12, 24, or 48 h), and dose and dosing interval should
be adjusted based on TDM results (C1-III).
2.6.2. Literature review
Immature renal function in neonates requires antibiotic dosage
adjustment. Population pharmacokinetic studies were performed to
determine the optimal dosage regimens for ABK. Kimura et al. [23]
calculated parameters of population pharmacokinetics involving 41
neonates to whom ABK was administered at 2e3 mg/kg twice daily,
and observed that ABK clearance (CLABK) markedly varied in neonates
with a borderline at 33weeksof PCA (gestational ageþ post natal age).
K. Okada et al. / J Infect Chemother 20 (2014) 1e5 5CLABK¼ 0.0238 bodyweight/serum creatinine level for PCAs of<33
weeks. CLABK¼ 0.0367 bodyweight/serum creatinine level for PCAs
of 33 weeks [24]. Initial dose was determined according to PCAs as
follows; PCAyounger than 28weeks: 4mg/kg 1/48h, 28e33weeks:
3mg/kg 1/24 h, 33e37weeks: 4mg/kg 1/24 h, 37weeks or older:
7mg/kg 1/24h [23]. Thedose anddosing interval shouldbe adjusted
based on the TDM results, and proposed trough concentration and
Cpeak are2mg/mLand7mg/mL, respectively. In addition, once-a-day
ABK administration targeting 9e20 mg/mL of Cpeak has been investi-
gated involving 14 neonates, in which the Cpeak was 15.2  4.3 mg/mL
and the trough valuewas 2.11.4 mg/mLwhen 6.2 0.4mg/kg of ABK
was administered at 24e48-h intervals [25]. In the postmarket survey
of patients in whom the blood ABK concentration was monitored in
patients with bacteremia and pneumonia, the results of once- and
twice-a-day administrations at 4e6 mg/kg/day was reported in chil-
dren. The number of patients studied, however, was insufﬁcient for
efﬁcacy evaluation [10].
2.7. Drug interaction
2.7.1. Executive summary
There is no particular interaction to be described.
2.8. Measuring method of blood concentration
2.8.1. Executive summary
External diagnostic reagents of the latex immunoturbidimetric
method will be supplied, replacing the FPIA method.
Although there may be no major problem in clinical setting,
caution is required regarding the following points:
a. In measurement methods utilizing antigeneantibody and
enzyme reactions (such as FPIA), cross-reactions occur and a
false high value may be obtained when other aminoglycosides
are present in the sample [26].
b. When b-lactams are present at a high level in the sample,
aminoglycosides are degraded. Thus, blood samples should be
immediately subjected to measurement or frozen [27e29].
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